215 related articles for article (PubMed ID: 19174554)
21. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array.
Jin X; Wu XX; Jin C; Inui M; Sugimoto M; Kakehi Y
Anticancer Drugs; 2012 Apr; 23(4):445-54. PubMed ID: 22205156
[TBL] [Abstract][Full Text] [Related]
22. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
23. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
Koschny R; Ganten TM; Sykora J; Haas TL; Sprick MR; Kolb A; Stremmel W; Walczak H
Hepatology; 2007 Mar; 45(3):649-58. PubMed ID: 17326159
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
25. RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.
Basit F; Humphreys R; Fulda S
J Biol Chem; 2012 Nov; 287(46):38767-77. PubMed ID: 22927431
[TBL] [Abstract][Full Text] [Related]
26. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP; Premkumar DR; Pollack IF
Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
von Pawel J; Harvey JH; Spigel DR; Dediu M; Reck M; Cebotaru CL; Humphreys RC; Gribbin MJ; Fox NL; Camidge DR
Clin Lung Cancer; 2014 May; 15(3):188-196.e2. PubMed ID: 24560012
[TBL] [Abstract][Full Text] [Related]
29. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
[TBL] [Abstract][Full Text] [Related]
30. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Tuthill MH; Montinaro A; Zinngrebe J; Prieske K; Draber P; Prieske S; Newsom-Davis T; von Karstedt S; Graves J; Walczak H
Oncogene; 2015 Apr; 34(16):2138-2144. PubMed ID: 24909167
[TBL] [Abstract][Full Text] [Related]
31. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Koschny R; Boehm C; Sprick MR; Haas TL; Holland H; Xu LX; Krupp W; Mueller WC; Bauer M; Koschny T; Keller M; Sinn P; Meixensberger J; Walczak H; Ganten TM
J Neuropathol Exp Neurol; 2014 Nov; 73(11):1034-46. PubMed ID: 25289891
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
Cardoso F; Durbecq V; Laes JF; Badran B; Lagneaux L; Bex F; Desmedt C; Willard-Gallo K; Ross JS; Burny A; Piccart M; Sotiriou C
Mol Cancer Ther; 2006 Dec; 5(12):3042-51. PubMed ID: 17148762
[TBL] [Abstract][Full Text] [Related]
35. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
[TBL] [Abstract][Full Text] [Related]
36. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Bruning A; Vogel M; Mylonas I; Friese K; Burges A
Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
[TBL] [Abstract][Full Text] [Related]
40. Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells.
Jiang L; Hao JL; Jin ML; Zhang YG; Wei P
Asian Pac J Cancer Prev; 2013; 14(10):6115-20. PubMed ID: 24289635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]